Juan C. Prieto

Madrid, MD 28805, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Antagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers.

Antagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers.

Journal: International journal of molecular sciences

Published: August 24, 2024

Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH).

Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH).

Journal: The Prostate

Published: July 16, 2021

Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists.

Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists.

Journal: Investigational new drugs

Published: May 23, 2019

Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.

Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.

Journal: The Prostate

Published: January 28, 2018

Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells.

Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells.

Journal: Molecular and cellular endocrinology

Published: September 22, 2016

Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells.

Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells.

Journal: Peptides

Published: June 15, 2016

Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.

Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.

Journal: Oncotarget

Published: December 21, 2015

VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells.

VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells.

Journal: Cellular signalling

Published: August 05, 2014

Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.

Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.

Journal: Investigational new drugs

Published: May 04, 2014

Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression.

Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression.

Journal: The international journal of biochemistry & cell biology

Published: November 18, 2013

Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice.

Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice.

Journal: Cancer letters

Published: January 23, 2013

Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells.

Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells.

Journal: Peptides

Published: July 25, 2012

Showing 1-12 of 16

Last Updated: 09/26/2026